Medical Devices
Technology
Health

Becton Dickinson

$234.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.68 (-0.71%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BDX and other stocks, options, ETFs, and crypto commission-free!

About

Becton, Dickinson and Co., also called Becton Dickinson, is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Read More The company operates through two worldwide business segments: BD Medical and BD Life Sciences. The BD Medical segment produces medical devices that are used in healthcare settings. This segment product includes needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Life Sciences segment produces products for the safe collection and transport of diagnostic specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal products and services in the Life Sciences segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; plated media; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunology and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Employees
76,032
Headquarters
Franklin Lakes, New Jersey
Founded
1897
Market Cap
63.57B
Price-Earnings Ratio
69.45
Dividend Yield
1.15
Average Volume
1.16M
High Today
$234.90
Low Today
$231.92
Open Price
$234.27
Volume
377.57K
52 Week High
$265.87
52 Week Low
$208.62

Collections

Medical Devices
Technology
Health
Medical
Healthcare
Pharmaceutical
Media
Cancer Prevention

News

Yahoo FinanceMay 16

Becton, Dickinson Muscles Through a Tough Quarter

Becton, Dickinson and Company (NYSE: BDX) had a tough second fiscal quarter. Some of it was expected: There was a difficult comparison given a couple of one-time factors that benefited the year-ago quarter. Some of it wasn't all that important: Distributors adjusted their inventories, which lowered sales in the quarter, though demand is what's important in the long term. And some of it could be a bigger deal: The Food and Drug Administration warned about the long-term effects of a class of products that the...

55
Yahoo FinanceMay 14

Jim Cramer Gives His Opinion On Becton Dickinson, Fox, Puma Biotech And More

On CNBC's "Mad Money Lightning Round," Jim Cramer said he would hold off for now from Village Farms International Inc (NASDAQ: VFF). He is not a buyer of Sailpoint Technologies Holdings Inc (NYSE: SAIL). Magellan Midstream Partners, L.P. (NYSE: MMP) has a 6.6 percent dividend yield, but Cramer wouldn't buy it. He thinks that stocks in the sector are some of the worse-acting stocks in the market. Scroll to continue with content Ad Cramer likes Becton Dickinson and Co (NYSE: BDX). He explained that the st...

84
ReutersMay 13

Becton Dickinson unit settles U.S. probe over unapproved medical devices

Becton Dickinson subsidiary CareFusion has agreed to pay $3.3 million to resolve claims that it bought and sold medical devices that did not have approval by the Food and Drug Administration, the Justice Department said on Monday.

83

Earnings

$2.37
$2.56
$2.74
$2.93
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
$2.58 per share
Actual
$2.59 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.